DEV Community: Market Research

Carcinoid Syndrome Diarrhea Treatment Market Growth Driven by Advanced Neuroendocrine Tumor Therapies

Market Research — Mon, 28 Sep 2026 12:48:38 +0000

The global carcinoid syndrome diarrhea treatment market was valued at USD 4.63 billion in 2025 and is projected to grow from USD 5.02 billion in 2026 to USD 9.57 billion by 2034, registering a CAGR of 8.4% during 2026–2034. North America dominated the market with a 41.6% share in 2025, while Asia Pacific is expected to register the fastest CAGR of 8.12% during the forecast period.

Market Size (2025): USD 4.63 Billion

Market Size (2026): USD 5.02 Billion

CAGR (Forecast Period): 8.4% during 2026–2034

Forecast Year: 2034

Projected Market Size (2034): USD 9.57 Billion

Dominant Region: North America – 41.6% share in 2025

Fastest Growing Region: Asia Pacific – 8.12% CAGR

Market Overview
Carcinoid syndrome diarrhea treatment comprises therapies used to manage persistent diarrhea associated with carcinoid syndrome, a condition linked to neuroendocrine tumors that release excessive hormones such as serotonin. The treatment landscape includes somatostatin analogs, serotonin-targeted therapies, supportive medications, and emerging targeted approaches used across hospitals, specialty clinics, and oncology centers.

Market expansion is supported by greater diagnosis of neuroendocrine tumors, advances in targeted treatments, and improving access to specialized cancer care. The treatment landscape is also evolving toward therapies that address the underlying mechanisms responsible for persistent diarrhea and provide more convenient long-term symptom management.

Growth Drivers
Loss of response to long-term somatostatin analog therapy is creating a need for additional treatment options. Some patients experience breakthrough diarrhea despite continuing therapy, encouraging the use of add-on medicines, dose adjustments, and targeted approaches to maintain symptom control. In March 2026, updated clinical information continued to highlight loss of response during prolonged somatostatin analog treatment, reinforcing the need for additional diarrhea-control strategies.

The development of oral therapies is also broadening treatment options for patients who rely on long-acting injectable therapies. In November 2025, Crinetics Pharmaceuticals randomized the first patient in the Phase 3 CAREFNDR trial evaluating once-daily oral paltusotine for carcinoid syndrome, with the study assessing bowel-movement frequency and flushing episodes.

Market Challenges
Treatment-related gastrointestinal effects can complicate long-term symptom management because patients may already experience substantial gastrointestinal symptoms from carcinoid syndrome. Somatostatin analog therapy can contribute to pancreatic exocrine insufficiency and diarrhea, while serotonin-targeted treatments may cause constipation and abdominal discomfort, requiring clinicians to distinguish treatment-related effects from disease symptoms.

The small patient population associated with carcinoid syndrome also makes large clinical trials difficult. Patient recruitment requires appropriate tumor characteristics, active symptoms, and consideration of previous somatostatin analog use and other causes of diarrhea, which can increase development complexity and costs.

Market Opportunities
Broader availability of therapies targeting neuroendocrine tumors creates opportunities for integrated treatment portfolios. Companies can combine medicines addressing the underlying tumor with therapies designed to control carcinoid syndrome symptoms, creating complementary treatment pathways for patients requiring both tumor management and symptom control.

In July 2025, Ipsen received European Commission approval for Cabometyx for previously treated advanced neuroendocrine tumors, expanding systemic treatment options for NET patients alongside its established Somatuline portfolio. Such developments create opportunities for pharmaceutical companies to strengthen integrated oncology and symptom-management offerings.

Segment Analysis
By treatment type, the somatostatin analog (SSA) therapy segment dominated the carcinoid syndrome diarrhea treatment market with a 49.8% share in 2025, valued at USD 2.31 billion. SSAs remain widely used for controlling hormone secretion and managing symptoms associated with carcinoid syndrome, supporting their leading position.

By distribution channel, hospital pharmacies accounted for the largest share in 2025 at 52.4%, with a market value of USD 2.43 billion. Meanwhile, the online pharmacies segment is projected to register the fastest growth at a CAGR of 8.34% during 2026–2034, supported by digital healthcare services, home delivery, and improved access to specialty medicines.

By end user, hospitals dominated the market with a 57.6% share in 2025, valued at USD 2.67 billion. Specialized oncology services, multidisciplinary treatment teams, and advanced diagnostic and therapeutic facilities support the segment's leading position. Cancer research institutes are expected to register the fastest growth at a CAGR of 7.48% during the forecast period.

Regional Analysis
North America held the largest position in the carcinoid syndrome diarrhea treatment market, accounting for a 41.6% share in 2025, equivalent to USD 1.93 billion. The region benefits from established healthcare infrastructure, specialized oncology services, favorable reimbursement conditions, and strong clinical research activity. The U.S. represents the largest market in the region, while Canada is supported by improving access to oncology care and rare-disease treatment.

Asia Pacific is projected to register the fastest regional CAGR of 8.12% during 2026–2034, accounting for 19.8% of the global market in 2025. Improving healthcare infrastructure, greater awareness of rare cancers, expanding access to advanced therapies, and rising healthcare expenditure are supporting growth across Japan, China, India, and other regional markets.

Europe accounted for 27.4% of the global market in 2025, while Latin America and the Middle East & Africa represented 6.3% and 4.9%, respectively. Specialized oncology services, rare-disease awareness, healthcare investment, and improved access to advanced treatments are supporting market development across these regions.

Competitive Landscape
The carcinoid syndrome diarrhea treatment market includes pharmaceutical companies developing somatostatin analogs, serotonin-targeted therapies, supportive treatments, and broader neuroendocrine tumor therapies. Competition is shaped by therapeutic efficacy, symptom-control capabilities, treatment convenience, clinical development, regulatory approvals, and access to specialized oncology markets.

Key companies include:

Lexicon Pharmaceuticals Inc.

Novartis International AG (Sandoz)

Pharmascience Inc.

Omega Laboratories Ltd.

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Ipsen Biopharmaceuticals Inc.

Sirtex Medical Limited

BTG International Ltd.

Wockhardt Ltd.

Recent Developments
In May 2026, TerSera Therapeutics advanced its oncology supportive-care portfolio with treatments for carcinoid syndrome symptoms, including therapies targeting hormone-related diarrhea management. In March 2026, Ipsen strengthened clinical support programs for Somatuline (lanreotide), which is used to manage neuroendocrine tumor-related symptoms, including carcinoid syndrome.

In December 2025, Novartis advanced long-acting somatostatin analog therapies for symptom control associated with carcinoid syndrome. In September 2025, TerSera Therapeutics expanded the availability of Xermelo (telotristat ethyl) for patients with carcinoid syndrome diarrhea that remains uncontrolled despite somatostatin analog therapy.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/carcinoid-syndrome-diarrhea-treatment-market

Future Outlook
The carcinoid syndrome diarrhea treatment market is expected to expand through 2034 as diagnosis of neuroendocrine tumors improves and targeted therapies become more accessible. Continued development of oral therapies, serotonin-targeted treatments, and complementary symptom-management approaches is expected to broaden treatment options for patients with persistent diarrhea.

Asia Pacific is expected to remain the fastest-growing regional market, while North America retains its leading position. Pharmaceutical companies are likely to focus on treatment convenience, sustained symptom control, integrated neuroendocrine tumor management, and specialized therapies for patients whose symptoms remain inadequately controlled with existing treatment approaches.

About Straits Research
Straits Research is a global market intelligence and consulting company providing industry research, strategic insights, customized consulting, and business intelligence solutions across diverse markets and industries.

Caravan and Motorhome Market Forecast 2026–2034: Trends, Growth and Opportunities

Market Research — Mon, 28 Sep 2026 12:08:02 +0000

The global caravan and motorhome market was valued at USD 59.73 billion in 2025 and is projected to grow from USD 63.73 billion in 2026 to USD 107.07 billion by 2034, registering a CAGR of 6.7% during 2026–2034. North America dominated the market with a 42.6% share in 2025, while Europe is expected to register the fastest CAGR of 8.64% during the forecast period.

Market Size (2025): USD 59.73 Billion

Market Size (2026): USD 63.73 Billion

CAGR (Forecast Period): 6.7% during 2026–2034

Forecast Year: 2034

Projected Market Size (2034): USD 107.07 Billion

Dominant Region: North America – 42.6% share in 2025

Fastest Growing Region: Europe – 8.64% CAGR

Market Overview
Caravans and motorhomes are recreational vehicles designed to provide mobile accommodation for travel, leisure, camping, and outdoor activities. Caravans are typically towable units, while motorhomes combine transportation and residential space in a single vehicle, with features such as sleeping areas, kitchens, seating, storage, and sanitation facilities.

The market is supported by road trips, outdoor recreation, camping tourism, and flexible travel preferences. Manufacturers are also broadening their portfolios across vehicle sizes, layouts, sleeping capacities, and price levels to address different consumer requirements.

Growth Drivers
Broader product portfolios are making recreational vehicles accessible to a wider range of buyers. Manufacturers are offering different layouts, vehicle sizes, sleeping capacities, and price points, allowing couples, families, first-time buyers, and experienced travelers to select vehicles according to their space and mobility requirements.

In July 2025, Ahorn Camp unveiled an 11-model recreational vehicle lineup comprising nine motorhomes and two campervans based on the fourth-generation Renault Master. Such portfolio expansion gives consumers greater choice across vehicle categories and travel requirements.

Market Challenges
Maintaining comfortable interior temperatures without excessive energy consumption remains a challenge for caravans and motorhomes. Heating and cooling systems consume onboard electricity or fuel, creating a trade-off between climate comfort and off-grid endurance while requiring compact equipment suited to constrained vehicle spaces.

In June 2026, Eberspächer introduced the Breezonic Slim Power roof-mounted climate system for recreational vehicles, offering up to 2.8 kW of cooling capacity along with a heat-pump function for heating.

Market Opportunities
Spacious and multifunctional interior designs provide manufacturers with opportunities to differentiate premium recreational vehicles. Space-efficient layouts can accommodate sleeping areas, kitchens, bathrooms, storage, and leisure facilities without substantially increasing vehicle dimensions.

In August 2026, Westfalia introduced the Columbus Liner with a three-level interior concept featuring a king-size bed, optional Sky Lounge, XXL rear storage, bathroom, kitchen, and optional energy packages. Such configurations create opportunities for manufacturers to add value through premium interiors and multifunctional designs.

Segment Analysis
By product type, the caravan segment dominated the caravan and motorhome market with a 52.4% share in 2025. Travel trailers, fifth-wheel trailers, folding camp trailers, and truck campers offer different combinations of towing flexibility, space, maneuverability, and camping convenience, supporting their use across recreational travel applications.

The motorhomes segment also represents a major part of the market, supported by consumers seeking integrated transportation and accommodation. Type A models appeal to buyers seeking spacious interiors and premium amenities, while Type B and Type C models offer compact dimensions, maneuverability, and flexible configurations for family travel.

By end-user, the fleet owners segment is projected to register the fastest growth at a CAGR of 8.21% during 2026–2034. Rental companies, tourism operators, recreational vehicle fleets, and businesses offering flexible travel and accommodation services are encouraging fleet expansion and modernization.

The direct buyers segment accounted for the larger share of end-user demand, supported by consumer ownership for leisure travel, family vacations, camping, and extended road trips.

Regional Analysis
North America held the largest position in the caravan and motorhome market, accounting for a 42.6% share in 2025 and reaching USD 25.44 billion. Strong recreational vehicle ownership, established road-trip culture, extensive highway infrastructure, and outdoor tourism support regional market development. The U.S. and Canada remain important markets due to established camping and recreational travel activities.

Europe is projected to register the fastest regional CAGR of 8.64% during 2026–2034, with the region accounting for 31.8% of global revenue in 2025. Recreational travel, camping tourism, improved campsite infrastructure, and flexible travel preferences are supporting market growth across Germany, the U.K., France, Spain, Italy, and other European markets.

Asia Pacific accounted for 16.7% of the global market in 2025 and is expected to grow at a CAGR of 8.12% during the forecast period. China and Japan are important regional markets, while Latin America and the Middle East & Africa are supported by domestic tourism, outdoor recreation, and expanding leisure infrastructure.

Competitive Landscape
The caravan and motorhome market is highly competitive, with manufacturers offering caravans, travel trailers, motorhomes, campervans, fifth-wheel RVs, and customized recreational vehicles. Competition is shaped by product variety, interior comfort, smart vehicle systems, energy efficiency, lightweight construction, off-grid capabilities, and connected technologies.

Key companies include:

THOR Industries Inc.

Swift Group

Forest River Inc.

Winnebago Industries Inc.

Bürstner GmbH & Co. KG

Triple E Recreational Vehicles

Hymer GmbH & Co. KG

Jayco Inc.

Dethleffs GmbH & Co. KG

Knaus Tabbert AG

Trigano SA

Recent Developments
In May 2026, THOR Industries unveiled next-generation motorhomes and travel trailers across its brands, incorporating smart connectivity, energy-efficient power systems, and expanded off-grid capabilities. In February 2026, Winnebago Industries introduced all-electric and hybrid-ready motorhome concepts featuring advanced lithium battery systems and integrated energy management technologies.

In October 2025, Swift Group expanded its manufacturing operations in the U.K. by increasing production capacity for caravans and motorhomes. In September 2025, Adria Mobil launched a new range of caravans and motorhomes featuring upgraded digital control systems, lightweight construction, and improved interior layouts.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/caravan-and-motorhome-market

Future Outlook
The caravan and motorhome market is expected to expand steadily through 2034 as recreational travel, outdoor tourism, road trips, and flexible accommodation preferences continue to support vehicle adoption. Manufacturers are expected to focus on lightweight construction, intelligent energy systems, connected features, and multifunctional interiors to address changing travel preferences.

Europe is expected to remain the fastest-growing regional market, while North America retains its leading position. Continued portfolio expansion across caravans, motorhomes, campervans, and specialized recreational vehicles will create opportunities across consumer ownership, rental fleets, and tourism-related applications.

Bioenergy Market Analysis: Growth Trends, Opportunities and Forecast to 2034

Market Research — Mon, 28 Sep 2026 12:05:06 +0000

The global bioenergy market was valued at USD 156.85 billion in 2025 and is projected to grow from USD 168.93 billion in 2026 to USD 305.79 billion by 2034, registering a CAGR of 7.7% during 2026–2034. North America dominated the market with a 38.4% share in 2025, while Asia Pacific is expected to register the fastest CAGR of 10.38% during the forecast period.

Market Size (2025): USD 156.85 Billion

Market Size (2026): USD 168.93 Billion

CAGR (Forecast Period): 7.7% during 2026–2034

Forecast Year: 2034

Projected Market Size (2034): USD 305.79 Billion

Dominant Region: North America – 38.4% share in 2025

Fastest Growing Region: Asia Pacific – 10.38% CAGR

Market Overview
Bioenergy is renewable energy produced from organic materials such as agricultural residues, wood, animal waste, food waste, and dedicated energy crops. These resources can be converted into electricity, heat, biogas, or biofuels through combustion, anaerobic digestion, fermentation, and other conversion processes.

The market is expanding across power generation, industrial heating, transportation, and renewable gas applications. Growing use of biomass resources for waste utilization and energy production is also broadening the role of bioenergy within diversified renewable energy systems.

Growth Drivers
Expansion of renewable gas infrastructure is supporting bioenergy deployment by increasing the availability of biomethane for industrial consumption, transportation, and injection into existing gas networks. In January 2026, ENGIE signed a 10-year biomethane purchase agreement with PepsiCo and began developing an anaerobic-digestion facility with annual production capacity of 60 GWh.

Long-term purchasing agreements and the ability to convert agricultural and food residues into storable energy are improving the commercial viability of bioenergy projects. These developments are creating additional revenue pathways for biomass and renewable-gas producers.

Market Challenges
Bioenergy projects require consistent access to suitable biomass, while agricultural residues, forestry materials, used oils, animal fats, and organic waste are also utilized by other industries. Seasonal availability, moisture content, transportation distance, sustainability certification, and competing uses can increase procurement costs and complicate project planning.

Sustainability verification across complex biomass supply chains is another challenge. Producers must establish traceable sourcing and evaluate lifecycle emissions, biodiversity, land use, soil, water, and food-security considerations as production capacity expands.

Market Opportunities
Biomass-derived sustainable aviation fuel (SAF) offers a significant commercial opportunity because long-distance aviation continues to require energy-dense liquid fuels. Alcohol-to-jet technologies can convert biomass-derived ethanol into SAF compatible with existing aircraft and fuel infrastructure.

In June 2026, Technip Energies, Airbus, Safran, and Tereos agreed to establish the Rebound joint venture for an alcohol-to-jet SAF project with planned annual production of approximately 160,000 tonnes. Such projects create revenue avenues for biofuel producers, technology providers, feedstock suppliers, and renewable-energy developers.

Segment Analysis
By product type, the solid biomass segment dominated the bioenergy market with a 41.5% share in 2025, valued at USD 65.09 billion. Wood pellets, agricultural residues, forestry by-products, and other solid biomass materials remain widely used for electricity and heat production across industrial, commercial, and utility-scale applications.

By technology, the biochemical processes segment is expected to grow at the fastest CAGR of 9.41% during 2026–2034. Anaerobic digestion and fermentation enable the conversion of agricultural residues, organic waste, and other biological feedstocks into biogas and biofuels while supporting waste-to-energy and circular-economy applications.

By feedstock, the agricultural waste segment accounted for a 34.7% share in 2025, valued at USD 54.43 billion. Crop stalks, husks, straw, manure, and agricultural processing by-products provide a broad feedstock base while creating opportunities to convert agricultural residues into useful energy.

By application, the transportation segment is projected to register the fastest CAGR of 9.82% during 2026–2034. Bioethanol, biodiesel, renewable fuels, and biomethane are gaining relevance in transport applications where direct electrification can be more challenging.

Regional Analysis
North America held the largest position in the bioenergy market, accounting for a 38.4% share in 2025 and reaching USD 60.23 billion. The region benefits from substantial biomass resources, renewable-energy investment, biofuel production, and initiatives focused on reducing greenhouse gas emissions.

Asia Pacific is projected to register the fastest CAGR of 10.38% during 2026–2034, supported by agricultural residue availability, renewable-energy investments, waste-to-energy deployment, and efforts to diversify energy systems. China, India, and Japan remain important markets across the region.

Europe accounted for 29.6% of the global market in 2025, while Latin America and the Middle East & Africa represented 5.1% and 3.7%, respectively. Brazil is an important Latin American market due to its agricultural and sugarcane industries, while renewable-energy investment and waste-to-energy initiatives are supporting bioenergy development in the Middle East & Africa.

Competitive Landscape
The bioenergy market includes renewable-energy developers, biomass technology providers, engineering companies, biofuel producers, waste-to-energy operators, and diversified energy companies. Competition is shaped by conversion technology, feedstock access, project development capabilities, production capacity, sustainability credentials, and regional infrastructure.

Key companies include:

Mitsubishi Heavy Industries Ltd

MVV Energie AG

A2A SpA

Hitachi Zosen Corp

BTG Biomass Technology Group

Babcock & Wilcox Volund A/S

Biomass Engineering Ltd

Orsted A/S

Enerkem

Fortum Oyj

ADM (Archer Daniels Midland Company)

INEOS Bio

Abengoa Bioenergy

Neste

Novozymes

Recent Developments
In June 2026, Neste expanded renewable-fuel production capacity at its Rotterdam refinery, strengthening its renewable diesel and sustainable aviation fuel portfolio. In May 2026, TotalEnergies and Quatra expanded their partnership to increase the collection and processing of used cooking oil across Europe for biofuel and circular-energy applications.

In November 2025, BP commissioned additional renewable natural gas facilities in the U.S., expanding its biogas portfolio. In September 2025, EnviTec Biogas commissioned a new biomethane plant in Germany to support renewable gas production for industrial and transportation applications.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/bioenergy-market

Future Outlook
The bioenergy market is expected to expand steadily through 2034 as renewable gas, biofuels, biomass-based power, and waste-to-energy technologies gain broader commercial use. Development of biomethane infrastructure and advanced biofuels is creating additional applications beyond conventional biomass power and heating.

Asia Pacific is expected to remain the fastest-growing regional market, while North America continues to hold a leading position. Greater utilization of agricultural residues, organic waste, used oils, and other biomass resources will support new bioenergy projects across transportation, power generation, heating, and renewable-gas applications.

Barley Malt Syrup Market to Record 1.8% CAGR as Specialty Malt Ingredients Gain Adoption

Market Research — Mon, 28 Sep 2026 11:37:42 +0000

The global barley malt syrup market was valued at USD 490.59 million in 2025 and is projected to grow from USD 499.42 million in 2026 to USD 576.03 million by 2034, registering a CAGR of 1.8% during 2026–2034. Europe dominated the market with a 36.4% share in 2025, while Asia-Pacific is expected to register the fastest CAGR of 7.18% during the forecast period.

Market Size (2025): USD 490.59 Million

Market Size (2026): USD 499.42 Million

CAGR (Forecast Period): 1.8% during 2026–2034

Forecast Year: 2034

Projected Market Size (2034): USD 576.03 Million

Dominant Region: Europe – 36.4% share in 2025

Fastest Growing Region: Asia-Pacific – 7.18% CAGR

Market Overview
Barley malt syrup is a natural sweetener produced by sprouting barley grains and converting their starches into sugars before concentrating the resulting liquid. Its malt flavor, color, moisture, viscosity, and fermentable sugars make it useful across bakery products, cereals, beverages, confectionery, brewing, and other processed foods.

The market is supported by the use of malt-based ingredients in clean-label and specialty food formulations. Manufacturers are also expanding liquid and dry malt extract portfolios for bakery, beverage, confectionery, pharmaceutical, and malted-food applications.

Growth Drivers
Preference for naturally derived and recognizable sweetening ingredients is supporting the adoption of barley malt syrup across food and beverage applications. Its ability to provide sweetness, malt flavor, color, and functional properties allows manufacturers to use a single ingredient across multiple formulations.

The broad commercial use of liquid malt extracts in bakery, confectionery, beverages, cereals, and malt-based foods is further supporting market expansion. Barmalt, for example, continued offering liquid malt and cereal extracts for several food and beverage applications in 2025.

Market Challenges
Maintaining consistent sweetness, color, viscosity, and flavor remains a challenge because final syrup characteristics depend on barley quality and tightly controlled malting and extraction processes. Producers must manage raw-material selection, germination, mashing, filtration, evaporation, pasteurization, and food-safety requirements throughout commercial production.

Gluten content also restricts the use of conventional barley malt syrup in products positioned for strict gluten-free consumers. This consideration can influence ingredient selection in bakery, cereal, snack, and health-focused food formulations.

Market Opportunities
Expansion into bakery, functional foods, specialty beverages, cereals, confectionery, and malt-based products creates commercial opportunities for malt ingredient suppliers. Companies can develop customized liquid malt extracts with different flavor, color, and functional profiles for specific food and beverage formulations.

Specialty ingredient producers can also generate revenue through differentiated organic, clean-label, and application-specific malt syrup grades. The Malt Company, for instance, continued expanding its liquid malt extract portfolio with multiple product grades for specialized industrial applications in 2025.

Segment Analysis
By nature, the conventional segment dominated the barley malt syrup market with a 68.2% share in 2025. Its position is supported by broad availability, established production processes, cost advantages, and extensive use as a sweetening and flavoring ingredient across food applications.

By extract type, the diastatic segment is projected to grow at the fastest CAGR of 5.94% during 2026–2034. Its enzyme activity supports fermentation, dough development, crust color, and texture, making it particularly relevant to bread and other bakery products.

By application, the bakery and confectionery segment accounted for a 46.3% share in 2025. Barley malt syrup is widely used in bread, cakes, cookies, chocolates, and other products for sweetness, flavor enhancement, coloring, moisture, and fermentation-related functions.

By sales channel, the B2C segment is expected to register the fastest CAGR of 6.36% during 2026–2034. Wider availability through supermarkets, specialty stores, and online platforms is supporting access to barley malt syrup among home bakers and specialty food consumers.

Regional Analysis
Europe held the largest position in the barley malt syrup market, accounting for a 36.4% share in 2025. The region is supported by established brewing and bakery industries and the use of malt-based ingredients across confectionery, beverages, cereals, and specialty foods.

Asia-Pacific is projected to register the fastest regional CAGR of 7.18% during 2026–2034. China and Japan are important markets, supported by expanding food and beverage manufacturing, bakery and confectionery production, beverage industries, and the use of natural and malt-based ingredients.

North America accounted for 28.7% of the global market in 2025, with the U.S. representing the largest contributor in the region. Latin America and the Middle East & Africa are also supported by expanding food processing, bakery, confectionery, brewing, and modern retail activities.

Competitive Landscape
The barley malt syrup market features ingredient manufacturers, malt producers, specialty food suppliers, and established global food ingredient companies. Competition is shaped by product quality, ingredient versatility, clean-label offerings, production capacity, application-specific formulations, and regional distribution capabilities.

Key companies include:

Malt Products Corporation

Cargill, Incorporated

Muntons plc

Maltexco S.A.

Imperial Malts Ltd.

Cereal Food Manufacturing Company

Briess Malt and Ingredients

Urban Platter

Eden Foods

Boortmalt

VIVESCIA

Recent Developments
In May 2026, Muntons plc expanded its liquid malt extract and barley malt syrup production capacity at its Stowmarket, U.K., facility to serve baking, brewing, and food-processing applications. In March 2026, Briess Malt & Ingredients Co. launched a new range of clean-label organic barley malt syrups for bakery, beverage, and snack manufacturers.

In December 2025, Malteurop Group expanded malt processing operations in Europe to increase production capacity for malt-derived ingredients. In September 2025, Cargill introduced a range of malt-based sweetening ingredients for clean-label bakery and cereal applications.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/barley-malt-syrup-market

Future Outlook
The barley malt syrup market is expected to maintain steady growth through 2034 as manufacturers broaden the use of malt-based ingredients across bakery, confectionery, beverages, cereals, snacks, and specialty foods. Product differentiation through organic, clean-label, and application-specific formulations is expected to create additional commercial opportunities.

Asia-Pacific is positioned as the fastest-growing regional market, while Europe is expected to retain its leading position. Continued investment in malt processing capacity, localized barley sourcing, and specialty extract portfolios will support the market's expansion across food and beverage applications.

Artificial Intelligence in Retail Market Analysis: Growth Trends, Opportunities and Forecast to 2034

Market Research — Thu, 24 Sep 2026 13:18:39 +0000

The global artificial intelligence in retail market was valued at USD 13.39 billion in 2025 and is projected to grow from USD 17.98 billion in 2026 to USD 190.31 billion by 2034, registering a CAGR of 34.3% during 2026-2034. North America dominated the market with a 38.4% share in 2025, while Europe is expected to register the fastest CAGR of 31.8%.

Market Size (2025): USD 13.39 Billion

Market Size (2026): USD 17.98 Billion

CAGR (Forecast Period): 34.3%

Forecast Year: 2034

Projected Market Size (2034): USD 190.31 Billion

Dominant Region: North America - 38.4%

Fastest Growing Region: Europe - 31.8% CAGR

Market Overview
Artificial intelligence in retail refers to the use of machine learning, deep learning, computer vision, natural language processing, and predictive analytics to improve retail operations and customer experiences. These technologies support personalization, inventory management, demand forecasting, customer service, fraud detection, and automated decision-making across online and physical retail environments.

The market is shifting toward more autonomous retail applications. Agentic AI can handle multi-step shopping activities, while computer vision systems can continuously monitor shelves, identify misplaced products, and provide real-time visibility into store conditions, helping retailers improve both customer experience and operational efficiency.

Growth Drivers
AI-based price optimization is strengthening adoption as retailers manage complex product assortments and frequent promotional campaigns. AI systems can analyze sales patterns, seasonal factors, and promotion performance to support faster pricing and merchandising decisions, creating greater use of retail AI platforms.

Demand forecasting is another important growth driver as consumer preferences, local events, and seasonal purchasing patterns become more difficult to predict. AI-powered forecasting tools combine sales information with real-time and localized signals to improve assortment, replenishment, and inventory planning.

Market Challenges
Regulatory uncertainty surrounding AI transparency, consumer protection, discrimination, and accountability can increase compliance requirements for retail technology providers. Changing rules can lengthen deployment cycles and require additional legal and governance resources, making large-scale implementation more complex.

AI-driven cybersecurity threats also create operational challenges as retailers connect AI systems with customer-facing and business-critical infrastructure. Sophisticated phishing, identity theft, and automated attacks can require stronger monitoring and security controls, increasing the resources needed to scale AI applications safely.

Market Opportunities
AI-powered customer service provides technology providers with opportunities to offer intelligent assistants for product searches, order support, returns, and post-purchase interactions. Subscription-based assistants, specialized service modules, and enterprise integrations can create recurring revenue streams across retail technology deployments.

AI-based fraud detection also creates opportunities for payment providers, cybersecurity companies, and retail technology firms. Platforms that analyze suspicious transactions, account abuse, and payment activity can generate revenue through fraud-monitoring subscriptions, risk analytics, and managed security services.

Segment Analysis
By offerings, the solutions segment accounted for a 68.7% share in 2025, supported by its broad use across retail analytics, automation, personalization, inventory management, and data-driven decision-making. The services segment is expected to grow at a CAGR of 30.4% during 2026-2034, driven by implementation, integration, customization, consulting, training, and technical-support requirements.

By type, the online segment accounted for a 57.8% share in 2025 and is expected to grow at a CAGR of 31.2% during 2026-2034, supported by e-commerce platforms, personalized digital shopping, online customer engagement, and AI-enabled retail operations.

By technology, the machine learning and deep learning segment accounted for a 61.5% share in 2025, supported by its ability to analyze large retail datasets, identify purchasing patterns, improve personalization, and automate complex decisions. The natural language processing segment is expected to grow at a CAGR of 31.4% during 2026-2034, supported by conversational commerce, customer-service automation, intelligent search, and sentiment analysis.

By deployment model, the cloud segment accounted for a 72.4% share in 2025 and is expected to grow at a CAGR of 31.6% during 2026-2034, supported by scalability, flexible access, lower infrastructure requirements, and real-time AI processing across distributed retail operations. By application, the predictive merchandising segment accounted for a 24.6% share in 2025, while the programmatic advertising segment is expected to grow at a CAGR of 31.5% during 2026-2034.

Regional Analysis
North America led the artificial intelligence in retail market with a 38.4% share in 2025, supported by advanced technology infrastructure and widespread adoption of AI across retail operations. In the U.S., approximately 17% of retail businesses were expected to use AI within the six-month outlook as of May 2026, while Canada's 2026 AI strategy supports broader business adoption and targets significant economic and employment gains from AI.

Europe is projected to register the fastest CAGR of 31.8% during 2026-2034, supported by digitalization and AI adoption initiatives. The European Union targets 75% of companies using cloud computing, big-data analysis, or AI by 2030, while the U.K., Germany, and France are also supported by expanding business adoption and digital-transition programs.

Asia Pacific accounted for 24.1% of the global market in 2025, supported by expanding digital commerce and national AI initiatives. China, Japan, South Korea, and India remain important markets, with China targeting more than 90% adoption of next-generation intelligent terminals and AI agents by 2030, South Korea planning KRW 3.1 trillion in regional AI transformation projects during 2026-2030, and India targeting USD 350 billion in e-commerce GMV by 2030.

Competitive Landscape
The artificial intelligence in retail market is moderately fragmented, with global technology companies, cloud-service providers, retail software vendors, AI platform developers, data analytics companies, and specialized retail-AI startups competing across personalization, demand forecasting, inventory management, computer vision, marketing, and intelligent shopping. Established players compete through AI infrastructure, enterprise integration, data capabilities, platform scalability, security, and application breadth, while emerging players focus on specialized models, generative and agentic AI, rapid deployment, automation, and personalized retail experiences.

Key companies include:

Accenture

Amazon Web Services Inc.

Google Inc.

Intel Corporation

IBM Corporation

Microsoft Corporation

Numenta Inc.

NVIDIA Corporation

Oracle Corporation

SAP SE

ViSenze Pte Ltd.

Recent Developments
In June 2026, Amazon expanded its AI capabilities across retail operations through AI-powered shopping assistants, personalized recommendations, inventory optimization, and automated fulfillment technologies. In May 2026, Walmart enhanced its AI-driven retail initiatives across supply-chain automation, customer personalization, and intelligent inventory management.

In April 2026, Microsoft expanded its retail AI solutions through advancements in Azure AI, Copilot tools, and AI-powered retail applications. In January 2026, Salesforce enhanced its Agentforce and Commerce Cloud AI capabilities to support customer service, personalized shopping experiences, and automated retail processes.

Future Outlook
The artificial intelligence in retail market is expected to maintain rapid growth through 2034 as retailers adopt AI for personalization, merchandising, inventory management, customer service, advertising, and store operations. Solutions, online retail, machine learning and deep learning, and cloud deployment are expected to remain important areas of adoption.

Agentic AI, computer vision, natural language processing, predictive merchandising, and AI-powered fraud detection are expected to shape the next phase of retail technology development. Greater integration of AI with commerce platforms, enterprise systems, and customer-facing applications can further expand the role of intelligent technologies across the retail ecosystem.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/artificial-intelligence-in-retail-market

About Straits Research
Straits Research is a global market intelligence and consulting company providing market research, strategic insights, competitive analysis, and advisory services across multiple industries. The company delivers research and consulting solutions that help businesses understand market dynamics, evaluate competitive environments, identify opportunities, and support informed strategic decisions.

Animal Model Market: USD 5.99 Billion Opportunity Driven by Next-Generation Research Models

Market Research — Thu, 24 Sep 2026 13:13:04 +0000

The global animal model market was valued at USD 2.91 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 5.99 billion by 2034, registering a CAGR of 8.36% during 2026-2034. North America dominated the market with a 41.8% share in 2025, while Europe is expected to register the fastest CAGR of 9.3%.

Market Size (2025): USD 2.91 Billion

Market Size (2026): USD 3.15 Billion

CAGR (Forecast Period): 8.36%

Forecast Year: 2034

Projected Market Size (2034): USD 5.99 Billion

Dominant Region: North America - 41.8%

Fastest Growing Region: Europe - 9.3% CAGR

Market Overview
Animal models are living organisms used in biomedical research to study disease mechanisms, drug efficacy, safety, pharmacokinetics, and potential therapeutic approaches before treatments advance to human clinical studies. Mice, rats, rabbits, guinea pigs, and other laboratory animals are selected according to specific research requirements.

The market is moving toward more human-relevant and genetically defined research models. Humanized animals are being developed to better reproduce human immune and genetic mechanisms, while AI-based phenotyping is helping researchers automate behavioral and disease assessment and generate more consistent quantitative results.

Growth Drivers
Preclinical drug development remains a major growth driver as pharmaceutical and biotechnology companies use animal models to evaluate candidate therapies for safety, efficacy, pharmacokinetics, and disease mechanisms. Oncology and cardiovascular research programs, among others, rely on specialized laboratory animals to generate preclinical evidence before clinical testing.

Genetically engineered disease models are also strengthening market adoption by allowing researchers to reproduce specific mutations and biological pathways. Customized models can support oncology, rare-disease, immunology, and other specialized research programs where conventional animals may not adequately represent human disease characteristics.

Market Challenges
Specialized animal supply constraints can disrupt research schedules, particularly for nonhuman primates and other highly specialized models. Procurement difficulties and transportation restrictions can raise acquisition costs and delay studies, creating operational pressure for research organizations and suppliers.

Alternative research methods are also reshaping the competitive environment. Organ-on-chip systems, organoids, computational models, and other human-focused approaches are receiving greater regulatory and research attention, encouraging companies in the animal-model ecosystem to diversify their offerings.

Market Opportunities
Veterinary drug development provides an opportunity for animal-model suppliers, animal-health companies, and contract research organizations to expand specialized preclinical services. Study-ready models, breeding programs, safety testing, pharmacokinetic studies, and efficacy packages can create recurring revenue opportunities across veterinary pharmaceutical research.

Vaccine research also creates revenue avenues for model developers and CROs through specialized animals, breeding programs, immune-response studies, and preclinical testing services. Providers with infectious-disease models and integrated study-support capabilities can serve biotechnology companies, vaccine developers, and research institutions.

Segment Analysis
By animal type, the mice segment accounted for a 48.7% share in 2025 and is expected to grow at a CAGR of 9% during 2026-2034. Their established use in biomedical research, genetic similarity to humans, standardized strains, and suitability for disease modeling and drug development support the segment's leading position.

By application, the drug discovery and development segment accounted for a 55.9% share in 2025 and is expected to grow at a CAGR of 9.1% during 2026-2034. Extensive use in preclinical drug testing, safety and efficacy evaluation, disease modeling, and therapeutic-candidate validation supports continued adoption.

By end user, the pharma and biotech companies segment accounted for a 58.6% share in 2025 and is expected to grow at a CAGR of 9% during 2026-2034. Preclinical research programs, drug-development pipelines, and safety testing requirements continue to support the use of standardized and specialized animal models.

Regional Analysis
North America led the animal model market with a 41.8% share in 2025. The U.S. market is being shaped by continued biomedical research funding and a greater focus on human-based research methods, including a planned NIH investment of more than USD 150 million in 2026. Canada is also supporting ethical animal research through USD 7 million in federal funding for 2026-2031 to strengthen animal-care standards.

Europe is projected to register the fastest CAGR of 9.3% during 2026-2034, supported by biomedical research activity and the development of alternative research methods. The U.K. is investing £22 million in 2026 to accelerate non-animal testing approaches, while Germany and France continue to support biomedical research through public funding and life-science programs.

Asia Pacific accounted for 21.4% of the global market in 2025, supported by expanding biomedical research infrastructure and government-backed life-science programs. China, Japan, South Korea, and India remain important markets, with research funding and laboratory-animal development programs supporting regional activity.

Competitive Landscape
The animal model market is moderately fragmented, with specialized animal-model developers, contract research organizations, laboratory-animal suppliers, biotechnology companies, and academic research providers competing across standard, genetically engineered, humanized, disease-specific, and patient-derived models. Established players compete through model quality, genetic characterization, breeding capacity, biosecurity, reproducibility, regulatory support, and global distribution, while emerging companies focus on CRISPR-based development, humanized models, specialized disease models, faster customization, and integrated preclinical services.

Key companies include:

Charles River Laboratories

The Jackson Laboratory

Taconic Biosciences, Inc.

genOway S.A.

Janvier Labs

Harbour BioMed

Crown Bioscience

Envigo RMS, LLC

Inotiv

BIOCYTOGEN

BioSpherix, Ltd.

Ozgene Pty

Transgenic Inc.

Hera Biolabs

B&K Universal

Recent Developments
In June 2026, Charles River Laboratories expanded its preclinical research capabilities through animal-model platforms, genetic models, and translational research services supporting pharmaceutical and biotechnology drug-development programs. In May 2026, The Jackson Laboratory advanced its genetically engineered mouse models and precision-medicine research solutions for disease modeling and biomedical applications.

In April 2026, Envigo, part of Inotiv, expanded its preclinical research capabilities through laboratory animal models, research services, and study-support solutions. In January 2026, Taconic Biosciences expanded its genetically engineered animal-model portfolio through customized research models and breeding technologies targeting oncology, immunology, and drug discovery research.

Future Outlook
The animal model market is expected to maintain steady growth through 2034 as pharmaceutical and biotechnology companies continue using specialized models for preclinical drug development, disease research, and therapeutic validation. Mice, drug discovery and development, and pharma and biotech applications are expected to remain important areas of market activity.

Humanized models, genetically engineered animals, AI-based phenotyping, and specialized disease models are expected to shape product development. At the same time, greater use of organoids, organ-on-chip systems, and computational methods will encourage animal-model providers to focus on human relevance, model customization, reproducibility, and integrated preclinical services.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/animal-model-market

Aluminum Composite Panels Market to Record 4.6% CAGR as Advanced Cladding Technologies Gain Adoption

Market Research — Thu, 24 Sep 2026 13:02:54 +0000

The global aluminum composite panels market was valued at USD 6.98 billion in 2025 and is projected to grow from USD 7.30 billion in 2026 to USD 10.46 billion by 2034, registering a CAGR of 4.6% during 2026–2034. North America dominated the market with a 34% share in 2025, while Asia Pacific is expected to register the fastest CAGR of 8.2%.

Market Size (2025): USD 6.98 Billion

Market Size (2026): USD 7.30 Billion

CAGR (Forecast Period): 4.6%

Forecast Year: 2034

Projected Market Size (2034): USD 10.46 Billion

Dominant Region: North America – 34%

Fastest Growing Region: Asia Pacific – 8.2% CAGR

Market Overview
Aluminum composite panels are lightweight, durable building materials made by bonding aluminum sheets to a non-aluminum core. Their combination of strength, weather resistance, thermal insulation, and design flexibility supports applications across building facades, interior decoration, signage, transportation, and other architectural uses.

The market is moving toward higher-performance panel technologies, particularly fire-resistant systems and architectural finishes. Intumescent coatings are being used to improve fire protection, while 3D-textured surfaces that replicate wood, stone, and other natural materials are expanding design options for exterior and interior applications.

Growth Drivers
Building renovation and facade-upgrade projects are supporting the use of lightweight cladding systems that can be installed over existing structures with fewer structural modifications. Prefabricated construction is also creating opportunities for factory-finished panels that reduce on-site work and support faster, more standardized building projects.

Modern construction projects increasingly require materials that combine aesthetics, durability, and installation efficiency. Aluminum composite panels meet these requirements across commercial buildings, residential projects, and contemporary facade applications, supporting wider adoption by contractors and building owners.

Market Challenges
Regulatory differences across countries can make product qualification and international expansion more complex for aluminum composite panel manufacturers. Variations in building codes, fire testing requirements, certification procedures, and testing capacity can increase the resources required to introduce products across multiple markets.

A shortage of qualified facade installers can also affect project execution. Insufficient technical expertise can delay installation and remediation work, making workforce availability an important operational consideration for panel manufacturers, contractors, and building-envelope specialists.

Market Opportunities
Building-integrated photovoltaic facades provide panel manufacturers and building-envelope providers with an opportunity to combine architectural cladding with solar-energy generation. Solutions such as those offered by ACP Factory create revenue avenues through specialized panels, facade integration, and renewable-energy building-envelope projects.

Recycled-content aluminum composite panels also create opportunities for suppliers targeting sustainability-focused construction. 3A Composites' ALUCOBOND® circular, which uses 89% recycled aluminum, demonstrates how premium panel products can address green-building specifications while creating differentiated revenue streams.

Segment Analysis
By type, the fire-resistant segment accounted for a 60% share in 2025, supported by enhanced fire safety, heat resistance, and compliance with building requirements. The anti-bacterial segment is expected to grow at a CAGR of 7.5% during 2026–2034, supported by applications in healthcare and other hygienic building environments.

By coating base, the PVDF segment accounted for a 45% share in 2025, owing to its weather resistance, durability, color retention, and suitability for exterior applications. The fire-retardant segment is projected to grow at a CAGR of 7.8% during 2026–2034, supported by stronger emphasis on flame-resistant construction materials.

By composition, the core material segment accounted for a 35% share in 2025 and is expected to grow at a CAGR of 7.1% during 2026–2034. Its contribution to structural stability, lightweight performance, insulation, and overall panel strength supports its leading position.

By application, the building and construction segment accounted for a 55% share in 2025 and is projected to grow at a CAGR of 7.3% during 2026–2034. Extensive use in facades, exterior cladding, interiors, and modern architectural projects supports continued adoption.

Regional Analysis
North America led the aluminum composite panels market with a 34% share in 2025. The region benefits from commercial construction, building-envelope upgrades, and renovation activity. U.S. nonresidential building construction spending is projected to grow by 3.0% in 2027, while commercial construction spending is expected to increase by 5.8%. Canada is also supported by a projected 5.9% increase in non-residential construction capital expenditures in 2026.

Asia Pacific is projected to register the fastest CAGR of 8.2% during 2026–2034, supported by infrastructure investment and construction activity. China, Japan, South Korea, and India represent key regional markets, with major infrastructure and transport investments supporting demand for modern building-envelope materials.

Europe accounted for a 22% share in 2025, with construction activity supported by infrastructure, public investment, and energy and digital-transition projects. The U.K., Germany, and France remain important markets, while Latin America and the Middle East & Africa continue to provide opportunities through construction, renovation, and architectural applications.

Competitive Landscape
The aluminum composite panels market is moderately fragmented, with global building-material manufacturers, specialized ACP producers, architectural product companies, and regional panel manufacturers competing across construction, signage, transportation, and industrial applications. Competition centers on fire performance, durability, surface quality, design range, certification, manufacturing consistency, recycled content, and distribution capabilities.

Key companies include:

Alumax Industrial Co. Ltd.

American Building Technologies Inc.

Alcoa Inc.

Shanghai Huayuan New Composite Materials Co. Ltd.

Mitsubishi Plastics Inc.

Jyi Shyang Industrial Co. Ltd.

Guangzhou Xinghe ACP Co. Ltd.

Msenco Metal Co., Ltd.

Recent Developments
In June 2026, 3A Composites expanded its aluminum composite panel portfolio by advancing lightweight, fire-resistant, and sustainable panel solutions for architecture, transportation, and industrial applications. In May 2026, Alcoa advanced sustainable aluminum materials and low-carbon production technologies supporting downstream aluminum-based applications.

In April 2026, Mitsubishi Chemical Group advanced its aluminum composite solutions with a focus on durability, design flexibility, and performance across construction, transportation, and industrial applications. In January 2026, Arconic expanded its architectural aluminum solutions portfolio with high-performance aluminum materials and facade technologies.

Future Outlook
The aluminum composite panels market is expected to maintain steady growth through 2034 as construction, renovation, facade modernization, and architectural design projects continue to support adoption. Fire-resistant panels, PVDF coatings, core materials, and building and construction applications are expected to remain important areas of market activity.

Recycled-content panels, building-integrated photovoltaics, advanced fire-protection coatings, and textured architectural surfaces are expected to shape product development. Greater emphasis on safety, sustainability, installation efficiency, and design flexibility will also influence competition across the market.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/aluminum-composite-panels-market

Computational Biology Market Growth Fueled by Large-Scale Genomics and Biopharmaceutical R&D

Market Research — Thu, 24 Sep 2026 12:53:19 +0000

The global computational biology market was valued at USD 7.08 billion in 2025 and is projected to grow from USD 7.99 billion in 2026 to USD 21.07 billion by 2034, registering a CAGR of 12.88% during 2026-2034. North America dominated the market with a 39.8% share in 2025, while Europe is expected to register the fastest CAGR of 18.91%.

Market Size (2025): USD 7.08 Billion

Market Size (2026): USD 7.99 Billion

CAGR (Forecast Period): 12.88%

Forecast Year: 2034

Projected Market Size (2034): USD 21.07 Billion

Dominant Region: North America - 39.8%

Fastest Growing Region: Europe - 18.91% CAGR

Market Overview
Computational biology combines biology, computer science, mathematics, and statistics to analyze complex biological data and understand genes, proteins, cells, and biological systems. Its applications span drug discovery, disease modeling, genomics, personalized medicine, bioinformatics, and clinical research.

The market is shifting toward AI-powered and multimodal computational platforms that can process increasingly complex biological datasets. Foundation models are being used to integrate multiple biological data types, predict molecular and genomic behavior, and support biological sequence design, creating broader applications across research and drug development.

Growth Drivers
AI-assisted drug discovery is strengthening the need for computational platforms that support target identification, virtual screening, molecular interaction analysis, and candidate prioritization. Pharmaceutical companies are increasingly using computational models to analyze molecular structures, predict binding affinity, and accelerate early-stage drug development.

Spatial transcriptomics and spatial proteomics are also expanding computational workloads by requiring tools that can analyze cellular location, tissue architecture, and molecular interactions. These capabilities are particularly relevant to cancer research, where spatial analysis can support biomarker discovery and characterization of tumor microenvironments.

Market Challenges
Restricted access to genomic datasets can make it difficult for computational biology companies to build and validate models using sufficiently diverse biological information. Privacy requirements, controlled-access procedures, and institution-specific data policies can also complicate commercial data partnerships and cloud-based analysis.

Regulatory uncertainty presents another challenge for companies seeking to move computational tools into clinical workflows. Unclear validation, documentation, and compliance requirements can lengthen commercialization timelines and increase the resources needed to establish clinical reliability.

Market Opportunities
Computational toxicology provides software companies with opportunities to develop predictive safety-assessment platforms for pharmaceutical, biotechnology, chemical, and agrochemical organizations. Commercial solutions such as Certara's ToxStudio demonstrate revenue avenues through software subscriptions, predictive modules, and specialized safety-analysis services.

Synthetic biology also creates opportunities for platform providers offering biological design, data management, automation, and workflow optimization tools. Companies such as Benchling demonstrate how subscription-based platforms, workflow modules, data services, and enterprise integrations can generate revenue across biotechnology research operations.

Segment Analysis
By application, the drug discovery and disease modeling segment accounted for a 34.7% share in 2025, supported by its use in target identification, biological interaction analysis, disease research, and drug development. The human body simulation software segment is expected to grow at a CAGR of 18.73% during 2026-2034, supported by virtual testing, physiological modeling, and treatment-response prediction.

By tool, the analysis software and services segment accounted for a 44.3% share in 2025 and is projected to grow at a CAGR of 18.29% during 2026-2034. Its role in genomic analysis, molecular research, disease modeling, and interpretation of large-scale datasets supports continued adoption.

By service, the in-house segment accounted for a 57.6% share in 2025, supported by greater control over sensitive research data and the ability to customize computational workflows. The contract segment is expected to grow at a CAGR of 18.54% during 2026-2034, supported by access to specialized expertise and flexible computational capabilities.

By end user, the industry and commercials segment accounted for a 61.3% share in 2025 and is projected to grow at a CAGR of 18.18% during 2026-2034. Drug discovery, genomic analysis, biomarker research, and data-driven biological research are supporting computational biology adoption across commercial organizations.

Regional Analysis
North America led the computational biology market with a 39.8% share in 2025, supported by advanced biomedical research infrastructure, strong biotechnology activity, and significant investment in computational methods and artificial intelligence. The U.S. remains the largest regional market, while Canada's genomics strategy is supporting commercialization, data access, and computational biology capabilities.

Europe is projected to register the fastest CAGR of 18.91% during 2026-2034, supported by life-science innovation programs, genomics initiatives, health-data infrastructure, and AI adoption. The U.K., Germany, and France represent important markets, with national programs supporting genomic research, precision medicine, and greater use of health data.

Asia Pacific accounted for a 22.4% share in 2025, supported by biotechnology development and government-led AI and research initiatives. China, Japan, South Korea, and India remain key markets, with investments in AI-driven scientific discovery, biotechnology, drug discovery, and national bioeconomy programs supporting regional expansion.

Competitive Landscape
The computational biology market is moderately fragmented, with life-science software companies, bioinformatics providers, genomics technology firms, computational drug-discovery companies, AI-driven biotechnology firms, and specialized research-platform providers competing across biological data analysis and drug development. Established players compete through platform breadth, validated algorithms, data resources, cloud capabilities, and enterprise integration, while emerging companies focus on AI-native models, multimodal data integration, automated workflows, and specialized biological applications.

Key companies include:

IBM

Thermo Fisher Scientific

Illumina

Agilent Technologies

Danaher Corporation

Revvity

DNAnexus

Schrödinger

Certara

Bio-Rad Laboratories

QIAGEN

Genedata

GeneBio

Compugen

Dassault Systèmes

Eurofins Scientific

Recent Developments
In June 2026, Chai Discovery signed a licensing agreement with Pfizer, enabling Pfizer to deploy Chai's AI platform and gain early access to the Chai-3 model. In May 2026, QIAGEN partnered with NVIDIA to integrate NVIDIA BioNeMo and accelerated computing with QIAGEN Digital Insights' curated bioinformatics knowledge bases.

These developments highlight the increasing integration of AI models, accelerated computing, and curated biological data into computational biology workflows, particularly across drug discovery and large-scale biological analysis.

Future Outlook
The computational biology market is expected to maintain strong growth through 2034 as pharmaceutical, biotechnology, academic, and research organizations expand their use of AI, advanced modeling, genomics, and biological data analysis. Analysis software and services, contract-based computational capabilities, and commercial applications are expected to remain important areas of expansion.

Multimodal foundation models, genome foundation models, spatial multi-omics, computational toxicology, and synthetic biology platforms are expected to shape product development. Greater integration of AI with biological datasets and high-performance computing can further expand the role of computational biology across drug discovery, disease research, and precision medicine.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/computational-biology-market

Chondroitin Sulfate Market Set for Growth Across Nutraceutical, Pharmaceutical and Cosmetic Applications

Market Research — Thu, 24 Sep 2026 12:46:56 +0000

The global chondroitin sulfate market was valued at USD 1.80 billion in 2025 and is projected to grow from USD 1.87 billion in 2026 to USD 2.54 billion by 2034, registering a CAGR of 3.9% during 2026-2034. North America dominated the market with a 38.7% share in 2025, while Europe is expected to register the fastest CAGR of 4.58%.

Market Size (2025): USD 1.80 Billion

Market Size (2026): USD 1.87 Billion

CAGR (Forecast Period): 3.9%

Forecast Year: 2034

Projected Market Size (2034): USD 2.54 Billion

Dominant Region: North America - 38.7%

Fastest Growing Region: Europe - 4.58% CAGR

Market Overview
Chondroitin sulfate is a naturally occurring compound found in cartilage, bones, and tendons and is widely used in nutraceuticals and pharmaceutical formulations, particularly for joint health and cartilage support. It is also used in personal care and cosmetics because of its water-binding and tissue-supporting properties.

The market is gradually moving beyond conventional animal-derived sources as manufacturers explore non-animal and fermentation-derived chondroitin sulfate. Clinical research is also gaining importance, with companies and researchers focusing on evidence that supports joint mobility, pain management, and cartilage-related applications.

Growth Drivers
The expanding use of chondroitin sulfate in joint health and osteoarthritis management is supporting market growth. Its established role in dietary supplements and pharmaceutical formulations, including combinations with glucosamine, continues to support adoption among consumers seeking products for mobility and joint care.

Clinical research is also strengthening the position of pharmaceutical-grade chondroitin sulfate in healthcare applications. In May 2026, researchers affiliated with Hospital Universitario La Paz and the Osteoarthritis Foundation International published an evaluation of prescription chondroitin sulfate, alone or with glucosamine, for knee osteoarthritis.

Market Challenges
Variations in raw-material sources, molecular characteristics, purity, and manufacturing processes can result in differences in chondroitin sulfate quality and clinical performance. Such variations make it difficult to establish consistent expectations across pharmaceutical, nutraceutical, and other formulations.

The industry's expanding research base also creates challenges in translating different formulations and experimental findings into standardized commercial products. Stronger characterization, traceability, quality control, and clinical validation remain important as applications move into more advanced healthcare areas.

Market Opportunities
Advanced biomaterials and drug-delivery systems create new avenues for chondroitin sulfate producers beyond conventional joint-health products. Its use in hydrogels, nanoparticles, tissue engineering, and targeted drug-delivery systems can support higher-value pharmaceutical and biomedical applications.

Specialized ingredient grades also provide opportunities for manufacturers to develop higher-purity and application-specific products. In April 2026, researchers at Hunan University published work on an injectable ROS-responsive hydrogel incorporating chondroitin sulfate and resveratrol-loaded liposomes for osteoarthritis, demonstrating the material's potential in advanced therapeutic delivery.

Segment Analysis
By source, the bovine segment accounted for a 42.6% share in 2025, valued at approximately USD 0.77 billion. Established extraction and purification processes, together with the availability of bovine cartilage as a commercial raw material, support its leading position across nutraceutical, pharmaceutical, and health-related applications.

By application, the personal care and cosmetics segment is projected to grow at a CAGR of 4.38% during 2026-2034, making it the fastest-growing application segment. Chondroitin sulfate's water-binding properties and potential role in skin-conditioning and moisturizing formulations are supporting its use in specialized personal care products.

Nutraceuticals and pharmaceuticals remain important application areas because of the established use of chondroitin sulfate in joint-health products. Animal feeds and other applications provide additional avenues for product development and diversification.

Regional Analysis
North America led the chondroitin sulfate market with a 38.7% share in 2025, reaching approximately USD 0.70 billion. The region benefits from established dietary supplement channels, consumer awareness of joint health, an aging population, and strong interest in preventive wellness. The U.S. represents a major market, while Canada continues to benefit from its expanding dietary supplement and wellness sector.

Europe accounted for 28.4% of the global market in 2025 and is projected to register the fastest CAGR of 4.58% during 2026-2034. Germany and the U.K. represent important markets, supported by aging populations, established nutraceutical sectors, and growing interest in joint and bone health.

Asia Pacific accounted for 22.9% of the market in 2025 and is projected to grow at a CAGR of 4.12%, supported by expanding nutraceutical markets and greater healthcare awareness. China, Japan, and India remain key markets, while Latin America and the Middle East & Africa continue to develop as consumer awareness of nutritional supplements and wellness products expands.

Competitive Landscape
The chondroitin sulfate market includes ingredient manufacturers, pharmaceutical-grade suppliers, nutraceutical companies, and specialized bioactive-ingredient producers. Competition is shaped by source quality, purity, traceability, manufacturing consistency, formulation support, and the development of alternative and higher-value chondroitin sulfate products.

Key companies include:

TSI Group Ltd

HeBei SanXin Industrial Group

Bioiberica S.A.U.

Sigma Aldrich Inc

Bio Gen Extracts Pvt Ltd

ZPD

Seikagaku Corporation

Sino Siam Biotechnique Company Ltd.

BRF

Bio-gen Extracts Pvt. Ltd.

Recent Developments
In May 2026, Bioiberica expanded its pharmaceutical-grade chondroitin sulfate portfolio with enhanced quality specifications and bioavailability support for premium joint-health formulations. The development strengthened its ingredient offering for nutraceutical and pharmaceutical manufacturers.

In September 2025, Bioiberica strengthened its global supply of pharmaceutical-grade chondroitin sulfate by expanding commercial support and technical services for joint-health and osteoarthritis applications. In August 2025, NOW Foods expanded its joint-health supplement portfolio with new formulations featuring alternative-source chondroitin sulfate.

Future Outlook
The chondroitin sulfate market is expected to maintain steady growth through 2034 as joint-health supplements, pharmaceutical formulations, and preventive wellness products continue to support the industry's established applications. Bovine-derived products will remain important, while alternative sourcing and fermentation-based production can broaden the available ingredient base.

Advanced biomaterials, targeted drug delivery, and specialized personal care formulations are expected to create additional growth avenues. Greater emphasis on purity, traceability, clinical evidence, and formulation consistency will also shape product development and competition across the market.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/chondroitin-sulfate-market

Carbon Footprint Management Market Size, Share, Growth and Forecast to 2034

Market Research — Wed, 23 Sep 2026 13:39:05 +0000

The global carbon footprint management market was valued at USD 10.71 billion in 2025 and is projected to grow from USD 11.40 billion in 2026 to USD 18.72 billion by 2034, registering a CAGR of 6.4% during 2026-2034. North America dominated the market with a 38.7% share in 2025, while Asia Pacific is expected to register the fastest CAGR of 14.27%.

Market Size (2025): USD 10.71 Billion

Market Size (2026): USD 11.40 Billion

CAGR (Forecast Period): 6.4%

Forecast Year: 2034

Projected Market Size (2034): USD 18.72 Billion

Dominant Region: North America - 38.7%

Fastest Growing Region: Asia Pacific - 14.27% CAGR

Market Overview
Carbon footprint management involves measuring, monitoring, analyzing, and reducing greenhouse gas emissions generated by organizational operations, products, and services. Software platforms and professional services help businesses track emissions, improve resource efficiency, meet reporting requirements, and support net-zero strategies.

The market is moving toward AI-powered carbon intelligence and integrated emissions-management platforms. In May 2026, Persefoni launched its Analytics Agent, enabling users to analyze emissions data through natural-language questions and generate targeted analysis, charts, and structured tables. Carbon accounting is also becoming more connected with agricultural supply chains, with CropX integrating with the Cool Farm Platform in May 2026 to support agricultural Scope 3 reporting.

Growth Drivers
Expansion of financed-emissions reporting is supporting adoption across banks, lenders, asset managers, and other financial institutions. Portfolio-level carbon measurement requires extensive emissions data and calculations across borrowers and investments, creating a need for specialized carbon accounting solutions. In March 2026, Capri Global Capital joined the Partnership for Carbon Accounting Financials to measure and disclose financed emissions across its lending portfolio.

Broader corporate sustainability programs are also strengthening the need for digital emissions-management tools. Businesses across manufacturing, transportation, utilities, commercial buildings, and technology sectors are using carbon management platforms to improve emissions visibility, support environmental reporting, and align operations with decarbonization objectives.

Market Challenges
Fragmented Scope 3 data remains a major challenge because companies often depend on suppliers that use different reporting formats, units, periods, and calculation methods. Missing primary information can require the use of estimates or spend-based emission factors, which can reduce the accuracy of corporate emissions inventories.

Maintaining consistency across evolving carbon accounting standards also creates technical and operational pressure. Changes in reporting frameworks, emission-factor databases, organizational boundaries, and calculation methodologies can require software providers and sustainability teams to update systems while maintaining transparent and comparable historical data.

Market Opportunities
Product-level carbon accounting creates new commercial opportunities for software providers and sustainability consultants. Solutions that connect corporate emissions inventories with detailed product and material information can help manufacturers compare suppliers, identify carbon-intensive inputs, support procurement decisions, and communicate environmental performance.

Greater harmonization of product-level carbon accounting can further expand this opportunity. In April 2026, ISO and the Greenhouse Gas Protocol advanced joint work on product-level carbon accounting through a global session focused on harmonizing methodologies, creating scope for technology providers to develop more standardized measurement and reporting solutions.

Segment Analysis
By component, the software segment accounted for a 64.2% share in 2025, supported by the adoption of digital platforms for carbon accounting, emissions tracking, sustainability reporting, and regulatory compliance. Professional services continue to support organizations with consulting, implementation, integration, auditing, and managed sustainability programs.

By deployment, the cloud segment accounted for a 57.4% share in 2025 and is expected to grow at a CAGR of 13.68% during 2026-2034. Scalability, real-time data access, lower deployment requirements, and integration with enterprise sustainability platforms are supporting cloud adoption.

By industry, the manufacturing segment accounted for a 28.9% share in 2025, supported by the need to monitor industrial emissions, improve energy efficiency, and meet environmental requirements. IT and telecom, transportation, commercial buildings, and utilities are also adopting carbon footprint management platforms for emissions monitoring and decarbonization initiatives.

Regional Analysis
North America led the carbon footprint management market with a 38.7% share in 2025, reaching USD 4.14 billion. The region benefits from corporate sustainability programs, environmental regulations, ESG reporting requirements, and adoption of digital carbon accounting solutions. The U.S. represents the largest regional contributor, while Canada continues to expand carbon reduction policies, clean-energy investments, and sustainability reporting.

Asia Pacific is projected to register the fastest CAGR of 14.27% during 2026-2034, supported by industrialization, climate policies, sustainability initiatives, and digital carbon management adoption. Japan's focus on carbon neutrality and corporate sustainability supports regional development, while China remains the largest market in Asia Pacific, supported by industrial decarbonization efforts, carbon trading programs, renewable-energy investments, and emissions monitoring.

Europe accounted for 29.4% of the global market in 2025 and is projected to grow at a CAGR of 11.36%, supported by climate targets, carbon regulations, ESG compliance, and green technology investments. The Middle East & Africa accounted for 4% of the market and is projected to grow at a CAGR of 9.86%, while investments in sustainable infrastructure and renewable energy continue to support adoption.

Competitive Landscape
The carbon footprint management market includes carbon accounting software providers, sustainability technology companies, environmental consulting firms, and enterprise technology providers. Competition centers on emissions-data accuracy, AI capabilities, reporting functionality, regulatory alignment, integration with enterprise systems, and the ability to manage complex Scope 1, Scope 2, and Scope 3 emissions.

Key companies include:

Ecova

Enablon

Greenstone+

IHS Markit

processMAP

Thinkstep

Verisae

Enviance

FirstCarbon Solutions

Schneider Electric SA

Natural Capital Partners

VelocityEHS

Aurecon Group

Carbon Solutions Global Ltd.

Carbon Trust

Carbon Footprint Ltd.

Recent Developments
In May 2026, Salesforce expanded its sustainability management solutions with enhanced carbon footprint tracking and emissions reporting capabilities. In March 2026, Microsoft expanded its sustainability platform with improved carbon accounting tools, AI-powered emissions analysis, and environmental data management solutions.

In December 2025, IBM expanded its Environmental Intelligence Suite with advanced analytics and AI-driven capabilities for carbon measurement, climate risk management, and sustainability reporting. In September 2025, SAP expanded its sustainability solutions portfolio with enhanced carbon accounting and emissions management tools to support enterprise decarbonization strategies.

Future Outlook
The carbon footprint management market is expected to maintain steady growth through 2034 as organizations strengthen emissions measurement, sustainability reporting, and decarbonization programs. Software platforms will remain central to carbon accounting, while cloud deployment is expected to gain further traction due to scalability and integration advantages.

AI-powered analytics, product-level carbon accounting, agricultural Scope 3 integration, and financed-emissions reporting are expected to broaden the market's application base. Greater standardization of carbon accounting methodologies and stronger integration with enterprise systems can further improve data quality, reporting consistency, and the commercial value of carbon management platforms.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/carbon-footprint-management-market

Breast Biopsy Market Outlook 2034: Imaging Innovation and Advanced Biopsy Techniques Drive Growth

Market Research — Wed, 23 Sep 2026 13:24:10 +0000

The global breast biopsy market was valued at USD 2.83 billion in 2025 and is projected to grow from USD 3.14 billion in 2026 to USD 7.12 billion by 2034, registering a CAGR of 10.8% during 2026-2034. North America dominated the market with a 38.6% share in 2025, while Asia Pacific is expected to register the fastest CAGR of 9.18%.

Market Size (2025): USD 2.83 Billion

Market Size (2026): USD 3.14 Billion

CAGR (Forecast Period): 10.8%

Forecast Year: 2034

Projected Market Size (2034): USD 7.12 Billion

Dominant Region: North America - 38.6%

Fastest Growing Region: Asia Pacific - 9.18% CAGR

Market Overview
Breast biopsy is a diagnostic procedure used to collect breast tissue or cells for laboratory examination when imaging identifies a suspicious abnormality. Core needle biopsy, fine-needle aspiration, vacuum-assisted biopsy, surgical biopsy, and liquid biopsy are among the approaches used to support breast cancer diagnosis and treatment decisions.

The market is also moving toward more precise image-guided procedures, contrast-enhanced mammography, automated systems, and robotic assistance. These technologies are helping healthcare providers improve lesion targeting, tissue acquisition, procedural workflow, and diagnostic accuracy.

Growth Drivers
Expansion of breast cancer screening programs is creating a broader diagnostic pathway for tissue sampling. In September 2025, NHS England reported that more than 2.1 million women underwent breast screening during the previous year, with approximately 18,000 cancers detected through the program, highlighting the role of screening in generating follow-up diagnostic procedures.

Advances in breast imaging are also supporting the use of image-guided biopsy systems. Contrast-enhanced mammography, ultrasound, stereotactic imaging, and MRI can help clinicians identify and target suspicious lesions, supporting more precise tissue sampling across different clinical settings.

Market Challenges
Procedure-related discomfort and complications can affect patient acceptance of breast biopsy procedures. Bruising, bleeding, hematoma, pain, and infection remain potential concerns, particularly when repeat tissue sampling is required.

Accessing small or technically difficult lesions can also create procedural challenges. Lesions located close to the chest wall, skin, implants, or other sensitive structures require precise targeting and adequate tissue retrieval, increasing the importance of accurate localization and specialized biopsy technologies.

Market Opportunities
Liquid biopsy creates an opportunity for diagnostic companies to expand beyond conventional tissue sampling through blood-based molecular assessment. Circulating tumor DNA and other biomarkers can support genomic profiling and may complement tissue biopsy when additional tissue is difficult to obtain.

Advanced biopsy platforms also provide opportunities for medical-device manufacturers to improve procedural efficiency and lesion targeting. Robotic systems, contrast-guided biopsy technologies, and integrated imaging platforms can create new revenue avenues through more automated and precise breast diagnostic workflows.

Segment Analysis
By product, the biopsy needles segment accounted for a 29.4% share in 2025, supported by their widespread use for tissue collection across core needle, fine-needle, and other minimally invasive breast biopsy procedures.

By biopsy type, the liquid breast biopsy segment is projected to grow at a CAGR of 10.36% during 2026-2034, supported by advances in circulating biomarker analysis, molecular diagnostics, and blood-based cancer assessment.

By guidance, the image-guided biopsy segment accounted for an 88.3% share in 2025, reflecting the widespread use of imaging technologies to locate suspicious abnormalities and guide accurate tissue sampling.

By application, the recurrence monitoring segment is expected to grow at a CAGR of 8.49% during 2026-2034, supported by greater emphasis on post-treatment surveillance and early identification of recurrent disease.

By end-user, the hospitals and surgical centers segment accounted for a 51.6% share in 2025, supported by access to advanced diagnostic equipment, trained specialists, surgical capabilities, and comprehensive breast cancer care services.

Regional Analysis
North America led the breast biopsy market with a 38.6% share in 2025, reaching USD 1.09 billion. The region benefits from established breast cancer screening programs, advanced healthcare infrastructure, and broad adoption of image-guided biopsy technologies. The U.S. represents the largest market in the region, while Canada continues to strengthen screening and diagnostic capabilities.

Asia Pacific is projected to record the fastest CAGR of 9.18% during 2026-2034, supported by greater breast cancer awareness, expanding healthcare infrastructure, broader access to diagnostic services, and adoption of advanced imaging and biopsy technologies. China and India represent important regional markets, with investments in cancer screening and specialized diagnostic services supporting market development.

Europe accounted for a 28.4% share in 2025, supported by established screening infrastructure and adoption of minimally invasive diagnostic procedures. Latin America accounted for 6.1%, while the Middle East & Africa represented 4.2% of the global market in 2025, with improvements in cancer-care infrastructure supporting continued market development.

Competitive Landscape
The breast biopsy market includes medical-device manufacturers, diagnostic technology companies, molecular testing providers, and specialized breast-health companies. Competition is shaped by biopsy accuracy, imaging integration, tissue acquisition, workflow efficiency, product safety, regulatory clearances, and technological innovation.

Key companies include:

Hologic, Inc.

Danaher Corporation

Becton, Dickinson and Company

QIAGEN

Illumina, Inc.

Merit Medical Systems

Medtronic

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd

Thermo Fisher Scientific, Inc.

GE HealthCare

Recent Developments
In January 2026, BD received U.S. FDA 510(k) clearance for the EnCor EnCompass Breast Biopsy and Tissue Removal System, a multi-modality platform designed to provide greater flexibility across breast imaging procedures. Mammotome, a Danaher business, also introduced the Mammotome Prima MR Dual Vacuum-Assisted Breast Biopsy System in February 2026 for use during MRI-guided breast biopsy procedures.

In April 2026, Hologic completed its acquisition by Blackstone and TPG, transitioning to private ownership while continuing its focus on women's health technologies. Hologic also received regulatory progress for its Brevera breast biopsy system during 2026 as it worked toward restoring availability of its 9G biopsy needle.

Future Outlook
The breast biopsy market is expected to maintain strong growth through 2034 as screening programs, advanced breast imaging, and precision diagnostics continue to expand the need for accurate tissue assessment. Image-guided procedures and biopsy needles will remain important components of clinical workflows, while liquid biopsy and advanced molecular diagnostics create additional avenues for innovation.

Robotic assistance, contrast-enhanced mammography-guided biopsy, integrated tissue-imaging systems, and technologies designed for technically difficult lesions are expected to shape product development. Greater emphasis on procedural efficiency, patient comfort, sample quality, and diagnostic precision will also influence competition across the market.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/breast-biopsy-market

Brand Protection Software Market Size, Share, Growth and Forecast to 2034

Market Research — Wed, 23 Sep 2026 13:10:41 +0000

The global brand protection software market was valued at USD 2.92 billion in 2025 and is projected to grow from USD 3.20 billion in 2026 to USD 6.61 billion by 2034, registering a CAGR of 9.51% during 2026-2034. North America dominated the market with a 39.5% share in 2025, while Asia Pacific is expected to register the fastest CAGR of 17.9%.

Market Size (2025): USD 2.92 Billion

Market Size (2026): USD 3.20 Billion

CAGR (Forecast Period): 9.51%

Forecast Year: 2034

Projected Market Size (2034): USD 6.61 Billion

Dominant Region: North America - 39.5%

Fastest Growing Region: Asia Pacific - 17.9% CAGR

Market Overview
Brand protection software helps organizations identify and address counterfeit products, trademark infringement, phishing, domain abuse, unauthorized sellers, and other digital threats. These platforms use artificial intelligence, machine learning, image recognition, and data analytics to monitor websites, marketplaces, social media, and other online channels.

The market is shifting toward automated monitoring and enforcement as brands manage increasingly complex digital footprints. AI-enabled systems can analyze large volumes of listings and digital signals, helping protection teams prioritize high-risk violations and respond more efficiently.

Growth Drivers
The spread of brand impersonation through lookalike websites, fake social profiles, fraudulent advertisements, and deceptive digital identities is strengthening the need for automated monitoring. Generative AI can also make fraudulent digital content easier to produce, increasing the volume and sophistication of threats faced by established brands.

The expansion of digital commerce is another important growth factor as brands operate across marketplaces, social platforms, websites, and emerging AI-powered shopping channels. Broader online exposure creates more points that require continuous monitoring and enforcement.

Market Challenges
The cost of comprehensive brand protection programs can create adoption barriers for smaller companies. Monitoring multiple brands, products, marketplaces, countries, languages, domains, and infringement types can increase subscription and enforcement costs as protection requirements become broader.

Rapidly changing counterfeit tactics also make continuous detection difficult. Infringers can modify product images, alter brand names, create new seller identities, and move activity between platforms, requiring software providers to continually improve detection models and monitoring coverage.

Market Opportunities
Expansion across emerging digital-commerce markets creates opportunities for brand protection providers to combine automated monitoring with local investigation and enforcement capabilities. Regional expertise can help software companies address marketplace-specific infringement patterns and serve both international and domestic brands.

AI-powered commerce protection is another revenue avenue for technology providers as product discovery and purchasing increasingly move into conversational and AI-assisted environments. Solutions capable of monitoring product recommendations, listings, and unauthorized sellers across these channels can broaden the scope of brand protection services.

Segment Analysis
By deployment, the cloud-based segment accounted for a 71.6% share in 2025, supported by scalability, lower infrastructure requirements, real-time monitoring, and easier integration with enterprise security systems. The segment is projected to grow at a CAGR of 16.4% during 2026-2034.

By application, counterfeit detection accounted for a 31.8% share in 2025, reflecting the need to identify fake products, protect brand reputation, and address revenue losses associated with unauthorized merchandise. The phishing detection segment is expected to grow at a CAGR of 17.3% during 2026-2034.

By organization size, large enterprises accounted for a 67.9% share in 2025, supported by broader digital operations, larger intellectual property portfolios, and greater exposure to online fraud and counterfeiting. The SMEs segment is projected to grow at a CAGR of 16.8% during 2026-2034, supported by increasing adoption of affordable cloud-based protection solutions.

By end user, e-commerce accounted for a 29.7% share in 2025, supported by the expansion of online marketplaces and the need to monitor digital sales channels. The segment is projected to grow at a CAGR of 17.5% during 2026-2034.

Regional Analysis
North America led the brand protection software market with a 39.5% share in 2025, supported by its large e-commerce ecosystem, established technology infrastructure, and widespread adoption of digital brand management and cybersecurity solutions. The U.S. represents the largest market in the region, while Canada is also expanding its use of digital monitoring and intellectual property protection technologies.

Asia Pacific is projected to record the fastest CAGR of 17.9% during 2026-2034, supported by rapid e-commerce expansion, digitalization, counterfeit activity, and greater awareness of intellectual property protection. China and Japan represent important regional markets, while India is emerging as an important market as businesses strengthen online brand monitoring and enforcement capabilities. Europe accounted for 27.4% of the global market in 2025, followed by Latin America at 6.4% and the Middle East & Africa at 4.9%.

Competitive Landscape
The brand protection software market includes specialized brand-monitoring providers, cybersecurity companies, intellectual property technology firms, and digital risk-management platforms. Competition is shaped by AI capabilities, monitoring coverage, detection accuracy, automated enforcement, platform integrations, geographic reach, and the ability to address evolving digital infringement methods.

Key companies include:

OpSec

PhishLabs

Red Points

Corsearch Inc.

Resolver

RiskIQ

Ruvixx

BrandShield

BrandVerity

Incopro

Recent Developments
In May 2025, Corsearch launched Zeal 2.0, an AI-native brand protection platform combining automated enforcement with image-recognition technology. In October 2025, Red Points introduced AI Commerce Protection to detect and remove counterfeit products appearing in AI-powered shopping environments, extending brand monitoring beyond conventional websites and marketplaces.

In March 2026, Akamai launched Brand Guardian, an AI-powered solution designed to detect brand impersonation across the web, social media, email, app stores, and the dark web. In October 2025, MarqVision introduced its Marq AI Brand Exposure Report to support network-level analysis of brand infringement beyond individual takedowns.

Future Outlook
The brand protection software market is expected to maintain strong growth through 2034 as companies seek to protect intellectual property, digital identities, customer trust, and revenue across increasingly complex online channels. Cloud-based platforms, counterfeit detection, and e-commerce applications are expected to remain important areas of adoption.

AI-powered detection, automated enforcement, image recognition, phishing monitoring, and protection across AI-enabled commerce environments are likely to shape product development. Greater regional expansion and integration with cybersecurity, e-commerce, and digital-risk platforms can also broaden the role of brand protection software across industries.

Click to Read the Complete Insights & Report: https://straitsresearch.com/report/brand-protection-software-market